41
Biotech deal activity seemed to be thriving in March 2026, at least with respect to mergers and acquisitions (M&As). In a rare move, the number of M&As beat licensing deals, with the latter focused on small molecules, antibodies, and artificial intelligence (AI).
Top biotech M&As of March 2026
The final month of the first quarter witnessed the highest number of M&As, with 12 major deals announced. Most of the buyouts were…